E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
advanced non-small cell lung cancer |
|
E.1.1.1 | Medical condition in easily understood language |
lung cancer which is not any more confined to the chest, but which has spread to the rest of the body |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061873 |
E.1.2 | Term | Non-small cell lung cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• to assess the safety of combining nivolumab, ipilimumab and up to 3 fractions of medium dose hypofractionated radiotherapy (mRT) to multiple tumor sites (1 to 4, with at least 1 site receiving 24Gy) • to explore the efficacy of combining IPI/NIVO/mRT in terms of objective response rates (ORR) and disease control rates (DCR) (short term) |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the ORR and DCR differences between tumors with a low PD-L1 and with negative PD-L1 expression after IPI/NIVO/mRT • To evaluate the effects of IPI/NIVO/mRT on PFS and OS (long term) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Histologically confirmed NSCLC, negative for EGFR, ALK or other treatable oncogenic drivers 2. WHO PS 0-2 3. Be willing and able to provide written informed consent for the trial. 4. Be above 18 years of age on day of signing informed consent. 5. Patients must have radiological disease progression on chemo-pembrolizumab 6. Have at least 1 lesion (up to 4) that is amenable to treatment with radiotherapy (3x8Gy as per judgement of the radiation oncologist), and at least 1 other unirradiated lesion which can serve as a measurable lesion for assessing tumor response based on RECIST 1.1. 7. Demonstrate adequate organ function, as deemed acceptable by the treating physician in the context of metastatic NSCLC |
|
E.4 | Principal exclusion criteria |
1. Patients with fast progressive disease as per judgement of the treating physician. 2. Patients who had received any radiotherapy during previous treatment with chemo-pembrolizumab. 3. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. 4. Active autoimmune disease requiring systemic steroid treatment within the past 3 years or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids. 5. Evidence of interstitial lung disease or active, non-infectious pneumonitis. 6. Active infection requiring systemic therapy. 7. A history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 8. Active Hepatitis B or C. 9. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 10. Has received prior therapy with an anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways (except pembrolizumab). 11. Has developed immune related adverse events on immunotherapy that necessitated stopping pembrolizumab indefinitely. 12. Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the pre-screening or screening visit through 23 weeks after the last dose of trial treatment. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Safety defined as the percentage of patients with adverse events (NCI CTCAE). Safety will be assessed throughout the study. The following possible immune related adverse events will be registered throughout the study: hyperthyroidism, hypothyroidism, adrenal insufficiency, hypophysitis, skin reactions, myositis, nephritis, pyrexia, pancreatitis, diabetes, increased transaminases, colitis, diarrhoea, nausea, pleural effusion, dyspnoea, pneumonia, pneumonitis. Other adverse events deemed related to the study medication will also be registered. The causal association will be determined by the investigators. The severity of adverse events will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2. Objective Response Rate (ORR) and Disease Control Rate (DCR) at 6 and 12 weeks after start of nivo-ipi-mRT |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
during the study and finally after finishing inclusion and follow up of the study |
|
E.5.2 | Secondary end point(s) |
1. Comparison of differences in ORR and DCR at 6 and 12 weeks after start of IPI/NIVO/mRT per PD-L1 group 2. PFS, as determined using Response Evaluation Criteria in Solid Tumors (RECIST) and defined as time from initiation of IPI/NIVO/mRT to the development of new lesions, progression of existing lesions, or death, whichever comes first. 3. Overall Survival (OS). Time frame: Baseline treatment-1 until death. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
during the study and finally after finishing inclusion and follow up of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |